GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
Published . Updated .
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
Directly affected
- GSK Gsk
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
Source: Nasdaq Markets
How far Acadia Healthcare (ACHC) has moved since 14 Sep 2026
Since the first closing price after “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC,” Acadia Healthcare (ACHC) is +10.34%. The S&P 500 fund (SPY) is +1.21% over the same days, a +9.13% difference versus the market.
Official trades in Acadia Healthcare (ACHC) around 14 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 15 days after publication, inside 30 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Where this story sits: Taiwan Strait
Taiwan Strait has 49 linked stories in the last 7 days and 49 in the last 30 on the page that also carries “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.” The recent pace is rising.
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
In “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
From Taiwan Strait to Acadia Healthcare (ACHC)
The 14 Sep 2026 story “GSK Presents Jideytro Data for Potential Use in First-Line NSCLC” names Acadia Healthcare (ACHC) because of Taiwan Strait.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“GSK Presents Jideytro Data for Potential Use in First-Line NSCLC” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.